Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Oct 17, 2024 · Potential pulmonary fibrosis therapy CAL101 fares well in study. CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety …
BMS-986278 declared breakthrough therapy for progressive PF
Oct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety …
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Now you know: Updates from my journey living with IPF November 5, 2024; My increasing interest in my family medical history October 29, 2024; Researchers will team up to …
New prototype therapy may repair IPF lung scarring by …
by Steve Bryson, PhD April 26, 2024. Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) …
Oral BMS-986278 slows lung decline in progressive PF, Phase 2...
Sep 25, 2023 · These findings are consistent with previously reported data from a group of idiopathic pulmonary fibrosis (IPF) patients also participating in the clinical trial, whose lung …
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
Aug 16, 2019 · The average life expectancy of patients with pulmonary fibrosis is three to five years after diagnosis. However, early detection of the disease is key to slowing progression, …
Primary goal met for IPF in Phase 3 clinical trial of nerandomilast
Sep 27, 2024 · A Phase 3 clinical trial testing Boehringer Ingelheim ’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary …
Study: ENV-101 improves IPF lung function, reverses fibrosis
by Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), …
First Patient Enrolled in Phase 3 Trial Testing BI 1015550
Oct 28, 2022 · by Steve Bryson, PhD October 28, 2022. Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and …
Top 10 Pulmonary Fibrosis Stories of 2021
Jan 3, 2022 · breathing exercises, Collagen turnover, esopremazole, MDM4, N115, pterostilbene, renin-angiotensin system, Salvianolic acid B, Top 10, TXR-1002, TXR-1007, Tyvaso, vitamin …